Dialysis patients treated with Epoetin α show improved exercise tolerance and physical function: A new analysis of the Canadian Erythropoietin Study Group trial

摘要: The risks/benefits of anemia treatment in dialysis patients have been redefined the US Epoetin α label. This analysis was carried out to determine if increasing hemoglobin (Hb) levels improve exercise tolerance and physical function anemic patients. is a new Canadian Erythropoietin Study Group trial, double-blind, randomized, placebo-controlled trial Subjects were 18 75 years old, on hemodialysis for >3 months, had baseline Hb <9.0 g/dL. Patients with history diabetes mellitus, ischemic heart disease, or severe/uncontrolled hypertension excluded. randomized receive target 9.5 11.0 g/dL (n=40) 11.5 13.0 (n=38), placebo (n=40). Results from Epoetin-α-treated arms combined this analysis. level, (Treadmill Stress Test 6-Minute Walk Test) patient-reported measures (Physical Summary domain Kidney Disease Questionnaire, 4 domains Sickness Impact Profile) reported at months 2, 4, 6. Differences statistically significant Stress, P=0.0001) (Kidney Questionnaire Physical, P=0.0001; Profile P=0.0015) across all time points compared placebo. Improvements seen 2 maintained through Dialysis receiving showed improved function. These findings should be considered as physicians weigh risks benefits treatment.